

Table 1 The PRISMA statement of example and our concerns

	The PRISMA statement	Example of the published MA	Our concerns
Title & Abstract	1. Title	Survival after neoadjuvant chemotherapy/chemoradiotherapy for resectable oesophageal carcinoma: an updated meta analysis	Identify the report as an update of MA/SR, or both.
	2. Structured summary	No special	—
Introduction	3. Rational	No special	—
	4. Objectives	No special	—
Methods	5. Protocol and registration	No special	—
	6. Eligibility criteria	No special	—
	7. Information sources	We included all trials from our previous meta-analysis and searched Medline, EMBASE, and Central (Cochrane clinical trials database) for studies published since January, 2006	Describe all information sources, even the studies identified from previous MA/SR.
	8. Search	No special	—
	9. Study selection	No special	—
	10. Data collection process	No special	—
	11. Data items	No special	—
	12. Risk of bias in individual studies	No special	—
	13. Summary measures	No special	—
	14. Planned methods of analysis	No special	—
Results	15. Risk of bias across studies	No special	—
	16. Additional analyses	No special	—
	17. Study selection	See the Figure 1 in the full text	A flow diagram included the studies which identified from previous MA/SR.
	18. Study characteristics	No special	—
	19. Risk of bias within studies	No special	—
	20. Results of individual studies	No special	—
	21. Syntheses of results	No special	—
Discussion	22. Risk of bias across studies	No special	—
	23. Additional analyses	No special	—
	24. Summary of evidence	No special	The item on “Summary of previous MA/SR” in the part of discussion might be needed, which included outcomes, results and its limitations etc. Maybe “Summary of table” will be the best choice.
	25. Limitations	No special	
26. Conclusions	No special		
Funding	27. Funding	No special	—

